FDA grants priority review to New Drug Application for selpercatinib for treatment of advanced RET fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer

The application for this inhibitor of native RET signalling is based on data from the LIBRETTO-001 Phase 1/2 trial in RET-altered lung and thyroid cancers. RET fusions have been identified in ~2% NSCLC, 10-20% of papillary and other thyroid cancers, and a subset of other cancers.


Biospace Inc.